Galderma Group AG announced its financial results for 2024, showcasing strong growth across all business segments.
The company reported a net sales increase of 12.3% on a constant currency basis, reaching $2.72 billion. The continued expansion of its injectable aesthetics and dermatological skincare divisions drove this growth.
Key financial highlights
- Core EBITDA surged by 26.6% to $651 million. The core EBITDA margin expanded to 23.9%, up from 21.3% in H1 2023.
- Gross profit margin improved to 71.8%, driven by favourable product mix and improved operational efficiencies.
- Injectable aesthetics and dermatological skincare saw double-digit growth, maintaining their positions as key revenue drivers.
Business segment performance
- Injectable aesthetics
The injectable aesthetics segment recorded a 19.4% sales increase in constant currency. This was fuelled by strong demand for Sculptra and Restylane. The company’s portfolio expansion, including new indications for its products and deeper penetration in key markets, contributed to this surge.
- Dermatological skincare
The dermatological skincare division saw a 15.1% growth in constant currency, with strong performances from Cetaphil and Alastin. Strategic marketing initiatives and new product launches played a significant role in this success.
- Therapeutic dermatology
The segment, which includes prescription-based treatments for skin conditions, grew by 2.4% in constant currency. This reflects a steady market demand and the company’s continued focus on innovation in medical dermatology.
Strategic Initiatives and Growth Drivers
- Geographical expansion: Galderma expands in Asia-Pacific and Latin America, capitalising on growing demand for medical and aesthetic dermatology solutions.
- Innovation and R&D: Galderma continues investing in R&D, with new product launches anticipated in the year’s second half.
- Operational efficiencies: Increased focus on supply chain optimisation and cost management contributed to margin expansion.
Future outlook
Galderma Group expects sustained double-digit growth driven by upcoming product launches and increased market penetration. The company continues investing in dermatological innovation to strengthen its position.
The company reaffirms its long-term strategy to strengthen its position as the global leader in dermatology.